Young-Hoon Kim1,2, Tackeun Kim1, Jin-Deok Joo1, Jung Ho Han1,2, Yu Jung Kim3, In Ah Kim4, Chang-Ho Yun5, Chae-Yong Kim1,2. 1. Department of Neurosurgery, Seoul National University Bundang Hospital, Seongnam-si, Korea. 2. Department of Neurosurgery, Seoul National University College of Medicine, Seoul, Korea. 3. Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam-si, Korea. 4. Department of Radiation Oncology, Seoul National University Bundang Hospital, Seongnam-si, Korea. 5. Department of Neurology, Seoul National University Bundang Hospital, Seongnam-si, Korea.
Abstract
BACKGROUND: A chemosensitizing effect of levetiracetam (LEV) has been suggested because LEV inhibits O-6 methylguanine-DNA methyltransferase (MGMT). However, the survival benefit of LEV has not been clinically documented. The objective of this study was to assess the survival benefit of LEV compared with other antiepileptic drugs as a chemosensitizer to temozolomide for patients with glioblastoma. METHODS: In total, 103 consecutive patients with primary glioblastoma who received concomitant chemoradiotherapy and adjuvant chemotherapy with temozolomide were retrospectively reviewed, and 58 patients (56%) received LEV during temozolomide chemotherapy for at least 3 months. A Cox regression survival analysis was performed to adjust for confounding factors, including age, extent of lesion, Karnofsky performance scale score, extent of removal, and MGMT promoter methylation status. RESULTS: The median progression-free survival (PFS) and overall survival (OS) for patients who received LEV in combination with temozolomide (PFS: median, 9.4 months; 95% confidence interval [CI], 7.5-11.3 months; OS: median, 25.7 months; 95% CI, 21.7-29.7 months) were significantly longer than those for patients who did not receive LEV (PFS: median, 6.7 months; 95% CI, 5.8-7.6 months; OS: median, 16.7 months; 95% CI, 12.1-21.3 months; P = .010 and P = .027, respectively). In multivariate analysis, the variables that were identified as significant prognostic factors for OS were preoperative Karnofsky performance scale score (hazard ratio [HR], 0.37; P = .016), MGMT promoter methylation (HR, 0.30; P = .002), and receipt of LEV (HR, 0.31; P < .001. CONCLUSIONS: LEV may provide a survival benefit in patients with glioblastoma who receive temozolomide-based chemotherapy. A prospective randomized study may be indicated.
BACKGROUND: A chemosensitizing effect of levetiracetam (LEV) has been suggested because LEV inhibits O-6 methylguanine-DNA methyltransferase (MGMT). However, the survival benefit of LEV has not been clinically documented. The objective of this study was to assess the survival benefit of LEV compared with other antiepileptic drugs as a chemosensitizer to temozolomide for patients with glioblastoma. METHODS: In total, 103 consecutive patients with primary glioblastoma who received concomitant chemoradiotherapy and adjuvant chemotherapy with temozolomide were retrospectively reviewed, and 58 patients (56%) received LEV during temozolomide chemotherapy for at least 3 months. A Cox regression survival analysis was performed to adjust for confounding factors, including age, extent of lesion, Karnofsky performance scale score, extent of removal, and MGMT promoter methylation status. RESULTS: The median progression-free survival (PFS) and overall survival (OS) for patients who received LEV in combination with temozolomide (PFS: median, 9.4 months; 95% confidence interval [CI], 7.5-11.3 months; OS: median, 25.7 months; 95% CI, 21.7-29.7 months) were significantly longer than those for patients who did not receive LEV (PFS: median, 6.7 months; 95% CI, 5.8-7.6 months; OS: median, 16.7 months; 95% CI, 12.1-21.3 months; P = .010 and P = .027, respectively). In multivariate analysis, the variables that were identified as significant prognostic factors for OS were preoperative Karnofsky performance scale score (hazard ratio [HR], 0.37; P = .016), MGMT promoter methylation (HR, 0.30; P = .002), and receipt of LEV (HR, 0.31; P < .001. CONCLUSIONS:LEV may provide a survival benefit in patients with glioblastoma who receive temozolomide-based chemotherapy. A prospective randomized study may be indicated.
Authors: Caroline Happold; Thierry Gorlia; Olivier Chinot; Mark R Gilbert; L Burt Nabors; Wolfgang Wick; Stephanie L Pugh; Monika Hegi; Timothy Cloughesy; Patrick Roth; David A Reardon; James R Perry; Minesh P Mehta; Roger Stupp; Michael Weller Journal: J Clin Oncol Date: 2016-01-19 Impact factor: 44.544
Authors: Sharon Berendsen; Meri Varkila; Jérôme Kroonen; Tatjana Seute; Tom J Snijders; Frans Kauw; Wim G M Spliet; Marie Willems; Christophe Poulet; Marike L Broekman; Vincent Bours; Pierre A Robe Journal: Neuro Oncol Date: 2015-09-29 Impact factor: 12.300
Authors: Jia-Shu Chen; Ross Clarke; Alexander F Haddad; Elaina J Wang; Michel Lacroix; Indra Neil Sarkar; Ramin Zand; Elizabeth S Chen; Steven A Toms Journal: J Neurooncol Date: 2022-01-04 Impact factor: 4.130
Authors: Kristin M Knudsen-Baas; Anders Engeland; Nils Erik Gilhus; Anette M Storstein; Jone F Owe Journal: J Neurooncol Date: 2016-07-04 Impact factor: 4.130
Authors: Tobias Walbert; Rebecca A Harrison; David Schiff; Edward K Avila; Merry Chen; Padmaja Kandula; Jong Woo Lee; Emilie Le Rhun; Glen H J Stevens; Michael A Vogelbaum; Wolfgang Wick; Michael Weller; Patrick Y Wen; Elizabeth R Gerstner Journal: Neuro Oncol Date: 2021-11-02 Impact factor: 13.029